Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...

A nationwide prospective cohort study was conducted of all Danish first-time users of the continuous levonorgestrel-releasing intrauterine system (52 mg, 19.5 mg, and 13.5 mg doses), among individuals ...

Please provide your email address to receive an email when new articles are posted on . Women using the intrauterine system had an increased risk for breast cancer vs. women who were hormonal ...

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing ...

The approval is based on results from a Phase 3 extension trial evaluating the efficacy and safety of Mirena. 2 “Now more than ever, it’s important to help ensure that women have the options they need ...